Logo Image
Opinion|Videos|February 10, 2025

Rethinking Uncomplicated UTI Treatment: Discussion of Aminoglycosides as an Alternative to Carbapenems

An expert briefly describes the study ‘Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated Urinary Tract Infections Caused by Extended-Spectrum β-lactamase-phenotype Gram-negative Enterobacterales,” including its objective, design, methodology, results, and key takeaways, and discusses how this data impacts the treatment of inpatient uncomplicated UTIs caused by extended-spectrum β-lactamase-producing Enterobacterales

Episodes in this series

Video content above is prompted by the following:

  • Briefly describe the study “Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated Urinary Tract Infections Caused by Extended-spectrum β-lactamase-phenotype Gram-negative Enterobacterales.”
  • What was the objective of this study?
  • How was this study designed, and what methodology was used?
  • What results were presented?
  • Provide your key takeaways from this study. How does this data impact how you treat inpatient UTIs caused by extended-spectrum β-lactamase-producing Enterobacterales?

Related Content